
Jeremy A. Squire

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7115593/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of human brain tumour initiating cells. Nature, 2004, 432, 396-401.	27.8	6,758
2	Identification of a cancer stem cell in human brain tumors. Cancer Research, 2003, 63, 5821-8.	0.9	3,675
3	Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome. New England Journal of Medicine, 2005, 353, 133-144.	27.0	1,787
4	Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens. Cell Stem Cell, 2009, 4, 568-580.	11.1	881
5	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology, 2013, 8, 823-859.	1.1	792
6	Mutations in SUFU predispose to medulloblastoma. Nature Genetics, 2002, 31, 306-310.	21.4	722
7	Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 2008, 26, 4268-4275.	1.6	674
8	Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Therapy, 1999, 6, 482-497.	4.5	576
9	High-resolution mapping of mammalian genes by in situ hybridization to free chromatin Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9509-9513.	7.1	515
10	Disruption of insulin–like growth factor 2 imprinting in Beckwith–Wiedemann syndrome. Nature Genetics, 1993, 5, 143-150.	21.4	423
11	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology and Laboratory Medicine, 2013, 137, 828-860.	2.5	415
12	Clinical implications of PTEN loss in prostate cancer. Nature Reviews Urology, 2018, 15, 222-234.	3.8	408
13	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors. Journal of Molecular Diagnostics, 2013, 15, 415-453.	2.8	397
14	TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes and Development, 2008, 22, 2677-2691.	5.9	378
15	Genetic Origin of Mutations Predisposing to Retinoblastoma. Science, 1985, 228, 501-503.	12.6	355
16	EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 2012, 12, 91.	2.6	325
17	Discordant KCNQ1OT1 imprinting in sets of monozygotic twins discordant for Beckwith-Wiedemann syndrome. Human Molecular Genetics, 2002, 11, 1317-1325.	2.9	322
18	Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 851-856.	7.1	321

#	Article	IF	CITATIONS
19	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	10.7	291
20	Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Human Molecular Genetics, 2008, 17, 1363-1372.	2.9	289
21	Immortal Human Pancreatic Duct Epithelial Cell Lines with Near Normal Genotype and Phenotype. American Journal of Pathology, 2000, 157, 1623-1631.	3.8	287
22	Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nature Genetics, 2001, 28, 220-221.	21.4	268
23	FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. British Journal of Cancer, 2007, 97, 678-685.	6.4	260
24	Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern Pathology, 2008, 21, 1451-1460.	5.5	254
25	Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Human Molecular Genetics, 2003, 12, 61R-68.	2.9	249
26	The role of <i>Alu</i> repeat clusters as mediators of recurrent chromosomal aberrations in tumors. Genes Chromosomes and Cancer, 2002, 35, 97-112.	2.8	239
27	A Radically Different Mechanism for <i>S</i> -Adenosylmethionine–Dependent Methyltransferases. Science, 2011, 332, 604-607.	12.6	230
28	Somatic inactivation of genes on chromosome 13 is a common event in retinoblastoma. Nature, 1983, 304, 451-453.	27.8	227
29	Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer. Current Genomics, 2008, 9, 394-408.	1.6	227
30	Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Human Molecular Genetics, 2001, 10, 2989-3000.	2.9	223
31	Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood, 2001, 97, 3581-3588.	1.4	197
32	<i>PTEN</i> genomic deletion is associated with pâ€Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. Journal of Pathology, 2009, 218, 505-513.	4.5	196
33	The Genetics of Osteosarcoma. Sarcoma, 2012, 2012, 1-11.	1.3	193
34	Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO Journal, 2004, 23, 3677-3688.	7.8	179
35	Extracellular Vesicles: Evolving Factors in Stem Cell Biology. Stem Cells International, 2016, 2016, 1-17.	2.5	179
36	Three-Color FISH Analysis of TMPRSS2/ERG Fusions in Prostate Cancer Indicates That Genomic Microdeletion of Chromosome 21 Is Associated with Rearrangement. Neoplasia, 2006, 8, 465-469.	5.3	165

#	Article	IF	CITATIONS
37	Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. Cancer Genetics and Cytogenetics, 2006, 169, 128-137.	1.0	151
38	Highâ€resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes and Cancer, 2003, 38, 215-225.	2.8	149
39	Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer. Cancer, 2010, 116, 5599-5607.	4.1	143
40	PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Modern Pathology, 2015, 28, 128-137.	5.5	136
41	Molecular genetics of Wiedemann-Beckwith syndrome. American Journal of Medical Genetics Part A, 1998, 79, 253-259.	2.4	135
42	Application of Microarrays to the Analysis of Gene Expression in Cancer. Clinical Chemistry, 2002, 48, 1170-1177.	3.2	132
43	A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma. Human Genetics, 1985, 70, 291-301.	3.8	126
44	Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genetics, 2011, 204, 138-146.	0.4	126
45	Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. Journal of Neurosurgery, 2000, 93, 437-448.	1.6	124
46	Identification of interactive networks of gene expression associated with osteosarcoma oncogenesis by integrated molecular profiling. Human Molecular Genetics, 2009, 18, 1962-1975.	2.9	119
47	The Role of RUNX2 in Osteosarcoma Oncogenesis. Sarcoma, 2011, 2011, 1-13.	1.3	118
48	CPC3 mutation analysis in a spectrum of patients with overgrowth expands the phenotype of Simpson-Golabi-Behmel syndrome. American Journal of Medical Genetics Part A, 2001, 102, 161-168.	2.4	115
49	Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy. BMC Cancer, 2010, 10, 202.	2.6	115
50	Genomic mechanisms and measurement of structural and numerical instability in cancer cells. Seminars in Cancer Biology, 2007, 17, 5-18.	9.6	114
51	Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes and Cancer, 2003, 36, 7-16.	2.8	109
52	Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells. Cancer Research, 2004, 64, 8526-8533.	0.9	108
53	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Laboratory Investigation, 2005, 85, 1392-1404.	3.7	107
54	Copy number alterations of <i>câ€MYC</i> and <i>PTEN</i> are prognostic factors for relapse after prostate cancer radiotherapy. Cancer, 2012, 118, 4053-4062.	4.1	105

#	Article	IF	CITATIONS
55	Malignant transformation in a ganglioglioma with anaplastic neuronal and astrocytic components. Report of a case with flow cytometric and cytogenetic analysis. Cancer, 1994, 73, 2862-2868.	4.1	102
56	Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression–Related Changes. Clinical Cancer Research, 2006, 12, 4043-4054.	7.0	102
57	Chromosomal Localization of DNA Amplifications in Neuroblastoma Tumors Using cDNA Microarray Comparative Genomic Hybridization. Neoplasia, 2003, 5, 53-62.	5.3	101
58	Analysis of Genomic Integrity and p53-Dependent G ₁ Checkpoint in Telomerase-Induced Extended-Life-Span Human Fibroblasts. Molecular and Cellular Biology, 1999, 19, 2373-2379.	2.3	100
59	<i>PTEN</i> genomic deletion is an early event associated with <i>ERG</i> gene rearrangements in prostate cancer. BJU International, 2011, 107, 477-485.	2.5	99
60	Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2001, 125, 87-99.	1.0	98
61	Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Research, 1999, 59, 1731s-1735s.	0.9	98
62	Morphological and cytogenetic analysis of human giant oocytes and giant embryos. Human Reproduction, 2002, 17, 2394-2401.	0.9	96
63	Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Research, 2002, 62, 3466-76.	0.9	96
64	Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. British Journal of Cancer, 2006, 94, 1452-1459.	6.4	95
65	Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer, 2006, 6, 237.	2.6	95
66	Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent ClC–DUX4 fusion gene event. Cancer Genetics and Cytogenetics, 2009, 195, 1-11.	1.0	95
67	Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer, 2013, 13, 549.	2.6	95
68	MicroRNA-34c Inversely Couples the Biological Functions of the Runt-related Transcription Factor RUNX2 and the Tumor Suppressor p53 in Osteosarcoma. Journal of Biological Chemistry, 2013, 288, 21307-21319.	3.4	95
69	Emerging role of PTEN loss in evasion of the immune response to tumours. British Journal of Cancer, 2020, 122, 1732-1743.	6.4	95
70	MYCN gene amplification in rhabdomyosarcoma. Cancer, 1994, 73, 2231-2237.	4.1	94
71	Mechanisms of loss of heterozygosity in retinoblastoma. Cytogenetic and Genome Research, 1992, 59, 248-252.	1.1	93
72	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 6229-6236.	1.6	93

#	Article	IF	CITATIONS
73	Amplification of a DEAD box protein gene in retinoblastoma cell lines Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7578-7582.	7.1	92
74	Fusion of the ets Transcription Factor TEL to Jak2 Results in Constitutive Jak-Stat Signaling. Blood, 1999, 93, 4354-4364.	1.4	92
75	Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. Journal of Clinical Oncology, 2007, 25, 2184-2190.	1.6	92
76	Profiling genomic copy number changes in retinoblastoma beyond loss of <i>RB1</i> . Genes Chromosomes and Cancer, 2007, 46, 118-129.	2.8	92
77	Minimal regions of chromosomal imbalance in retinoblastoma detected by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2001, 129, 57-63.	1.0	91
78	Plk4 is required for cytokinesis and maintenance of chromosomal stability. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6888-6893.	7.1	91
79	Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecologic Oncology, 2013, 130, 269-274.	1.4	91
80	lsochromosome 6p, a unique chromosomal abnormality in retinoblastoma: Verification by standard staining techniques, new densitometric methods, and somatic cell hybridization. Human Genetics, 1984, 66, 46-53.	3.8	90
81	Prognostic impact of chromosomal aberrations in Ewing tumours. British Journal of Cancer, 2002, 86, 1763-1769.	6.4	89
82	A method for accurate detection of genomic microdeletions using real-time quantitative PCR. BMC Genomics, 2005, 6, 180.	2.8	89
83	Chromosome 6p amplification and cancer progression. Journal of Clinical Pathology, 2007, 60, 1-7.	2.0	89
84	Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. Journal of Clinical Investigation, 2010, 120, 3310-3325.	8.2	89
85	<i>ASAP1</i> , a Gene at 8q24, Is Associated with Prostate Cancer Metastasis. Cancer Research, 2008, 68, 4352-4359.	0.9	87
86	Is the EWS/FLI-1 fusion transcript specific for Ewing sarcoma and peripheral primitive neuroectodermal tumor? A report of four cases showing this transcript in a wider range of tumor types. American Journal of Pathology, 1996, 148, 1125-38.	3.8	85
87	Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma. Neurosurgical Focus, 2005, 19, 1-17.	2.3	83
88	FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma. Journal of Clinical Pathology, 2010, 63, 630-634.	2.0	83
89	Multilevel Whole-Genome Analysis Reveals Candidate Biomarkers in Clear Cell Renal Cell Carcinoma. Cancer Research, 2012, 72, 5273-5284.	0.9	83
90	Direct Profiling of Cancer Biomarkers in Tumor Tissue Using a Multiplexed Nanostructured Microelectrode Integrated Circuit. ACS Nano, 2009, 3, 3207-3213.	14.6	82

#	Article	IF	CITATIONS
91	Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics, 1995, 26, 138-141.	2.9	81
92	Molecular cytogenetic analysis of head and neck squamous cell carcinoma: By comparative genomic hybridization, spectral karyotyping, and expression array analysis. Head and Neck, 2002, 24, 874-887.	2.0	81
93	High-Resolution Mapping of Genomic Imbalance and Identification of Gene Expression Profiles Associated with Differential Chemotherapy Response in Serous Epithelial Ovarian Cancer. Neoplasia, 2005, 7, 603-IN20.	5.3	81
94	The use of whole genome amplification in the study of human disease. Progress in Biophysics and Molecular Biology, 2005, 88, 173-189.	2.9	80
95	Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma. Oncogene, 1995, 10, 1417-22.	5.9	80
96	The human UDP-N-Acetylglucosamine:alpha-6-d-Mannoside-beta-1,2-N-Acetylglucosaminyltransferase II Gene (MGAT2). Cloning of Genomic DNA, Localization to Chromosome 14q21, Expression in Insect Cells and Purification of the Recombinant Protein. FEBS Journal, 1995, 231, 317-328.	0.2	78
97	Phase II study of PX-866 in recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1270-4.	1.2	77
98	Tumour induction by the retinoblastoma mutation is independent of N-myc expression. Nature, 1986, 322, 555-557.	27.8	76
99	Application of Comparative Genomic Hybridization, Spectral Karyotyping, and Microarray Analysis in the Identification of Subtype-Specific Patterns of Genomic Changes in Rhabdomyosarcoma. Neoplasia, 1999, 1, 262-275.	5.3	76
100	Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene, 2003, 22, 1978-1987.	5.9	76
101	Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data. Cancer Genetics, 2014, 207, 474-488.	0.4	76
102	Infrequent genomic rearrangement and normal expression of the putative RB1 gene in retinoblastoma tumors Molecular and Cellular Biology, 1988, 8, 2082-2088.	2.3	75
103	Chromosomal instability in osteosarcoma and its association with centrosome abnormalities. Cancer Genetics and Cytogenetics, 2003, 144, 91-99.	1.0	75
104	Highâ€resolution array CGH identifies novel regions of genomic alteration in intermediateâ€risk prostate cancer. Prostate, 2009, 69, 1091-1100.	2.3	75
105	Glypicans: a growing trend. Nature Genetics, 1996, 12, 225-227.	21.4	74
106	Brca1 required for T cell lineage development but not TCR loci rearrangement. Nature Immunology, 2000, 1, 77-82.	14.5	74
107	The RAC-1/2 endonuclease causes genomic instability and controls CNS complications of lymphoblastic leukemia in p53/Prkdc-deficient mice. Cancer Cell, 2003, 3, 37-50.	16.8	73
108	PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Modern Pathology, 2013, 26, 435-447.	5.5	73

#	Article	IF	CITATIONS
109	The Role of Telomere Maintenance in the Spontaneous Growth Arrest of Pediatric Low-Grade Gliomas. Neoplasia, 2006, 8, 136-142.	5.3	72
110	Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenetic and Genome Research, 2008, 122, 5-15.	1.1	72
111	In Vitro Analysis of Integrated Global High-Resolution DNA Methylation Profiling with Genomic Imbalance and Gene Expression in Osteosarcoma. PLoS ONE, 2008, 3, e2834.	2.5	71
112	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	5.5	71
113	A role for Brca1 in chromosome end maintenance. Human Molecular Genetics, 2006, 15, 831-838.	2.9	70
114	Comparative genomic hybridization analysis identifies gains of 1p35â^1/4p36 and chromosome 19 in osteosarcoma. Cancer Genetics and Cytogenetics, 2001, 130, 14-21.	1.0	69
115	Constitutional UPD for chromosome 11p15 in individuals with isolated hemihyperplasia is associated with high tumor risk and occurs following assisted reproductive technologies. American Journal of Medical Genetics, Part A, 2006, 140A, 1497-1503.	1.2	69
116	TMPRSS2-ERG and PTEN loss in prostate cancer. Nature Genetics, 2009, 41, 509-510.	21.4	69
117	Inactivation of 14-3-3Ï, Influences Telomere Behavior and Ionizing Radiation-Induced Chromosomal Instability. Molecular and Cellular Biology, 2000, 20, 7764-7772.	2.3	68
118	Recurrent anomalies of 6q25 in chondromyxoid fibroma. Human Pathology, 2000, 31, 306-311.	2.0	67
119	Characterization of human hepatocyte lines derived from normal liver tissue. Hepatology, 1994, 19, 1390-1399.	7.3	66
120	Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. International Journal of Oncology, 2007, 30, 5-17.	3.3	66
121	Cloning of the esterase D gene: a polymorphic gene probe closely linked to the retinoblastoma locus on chromosome 13 Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 6573-6577.	7.1	65
122	Role of Pirh2 in Mediating the Regulation of p53 and c-Myc. PLoS Genetics, 2011, 7, e1002360.	3.5	65
123	Murine Pif1 Interacts with Telomerase and Is Dispensable for Telomere Function In Vivo. Molecular and Cellular Biology, 2007, 27, 1017-1026.	2.3	64
124	Malignant myeloid transformation with isochromosome 7q in Shwachman–Diamond syndrome. Leukemia, 1998, 12, 1591-1595.	7.2	63
125	Renal Abnormalities in Beckwith-Wiedemann Syndrome Are Associated with 11p15.5 Uniparental Disomy. Journal of the American Society of Nephrology: JASN, 2002, 13, 2077-2084.	6.1	62
126	<i>PTEN</i> deletion and heme oxygenaseâ€1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome. Journal of Pathology, 2011, 224, 90-100.	4.5	62

#	Article	IF	CITATIONS
127	Collaboration of Brca1 and Chk2 in tumorigenesis. Genes and Development, 2004, 18, 1144-1153.	5.9	61
128	Applications of SKY in Cancer Cytogenetics. Cancer Investigation, 2002, 20, 373-386.	1.3	60
129	Cfr and RlmN Contain a Single [4Fe-4S] Cluster, which Directs Two Distinct Reactivities for <i>S</i> -Adenosylmethionine: Methyl Transfer by S _N 2 Displacement and Radical Generation. Journal of the American Chemical Society, 2011, 133, 19586-19589.	13.7	60
130	ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. Clinical Cancer Research, 2015, 21, 2569-2579.	7.0	60
131	Extracellular vesicles in ovarian cancer: applications to tumor biology, immunotherapy and biomarker discovery. Expert Review of Proteomics, 2016, 13, 395-409.	3.0	60
132	Advances in the detection of chromosomal aberrations using spectral karyotyping. Clinical Genetics, 2001, 59, 65-73.	2.0	58
133	Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: A preclinical model. International Journal of Cancer, 2003, 104, 36-43.	5.1	58
134	PTENâ€deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells. Prostate, 2019, 79, 969-979.	2.3	58
135	Molecular genetic, cytogenetic, and immunohistochemical characterization of alveolar soft-part sarcoma: Implications for cell of origin. Cancer, 1992, 70, 2444-2450.	4.1	57
136	Loss of Imprinting of Human Insulin-like Growth Factor II Gene, IGF2, in Acute Myeloid Leukemia. Biochemical and Biophysical Research Communications, 1997, 231, 466-472.	2.1	57
137	Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16415-16420.	7.1	57
138	Recurrent RECQL4 Imbalance and Increased Gene Expression Levels Are Associated with Structural Chromosomal Instability in Sporadic Osteosarcoma. Neoplasia, 2009, 11, 260-IN6.	5.3	57
139	Molecular biology of Beckwith-Wiedemann syndrome. , 1996, 27, 462-469.		55
140	Imprinting Status of 11p15 Genes in Beckwith–Wiedemann Syndrome Patients with CDKN1C Mutations. Genomics, 2001, 74, 370-376.	2.9	55
141	Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer, 2001, 91, 2156-2164.	4.1	55
142	Fluorescence In Situ Hybridization (FISH). Current Protocols in Cell Biology, 2004, 23, Unit 22.4.	2.3	55
143	A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. Prostate, 2015, 75, 1206-1215.	2.3	55
144	Decitabine-Induced Demethylation of 5′ CpG Island in GADD45A Leads to Apoptosis in Osteosarcoma Cells. Neoplasia, 2008, 10, 471-480.	5.3	54

#	Article	IF	CITATIONS
145	A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer. British Journal of Cancer, 2015, 112, 1215-1222.	6.4	54
146	A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. Leukemia, 1994, 8, 236-44.	7.2	54
147	Association of Alveolar Rhabdomyosarcoma with the Beckwith-Wiedemann Syndrome. Pediatric and Developmental Pathology, 2001, 4, 550-558.	1.0	53
148	Abnormalities in villin gene expression and canalicular microvillus structure in progressive cholestatic liver disease of childhood. Lancet, The, 2003, 362, 1112-1119.	13.7	53
149	<i>PTEN</i> genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications. Genes Chromosomes and Cancer, 2012, 51, 149-160.	2.8	53
150	Molecular genetics of Beckwith-Wiedemann syndrome. Current Opinion in Pediatrics, 1997, 9, 623-629.	2.0	52
151	Relaxation of Imprinting of Human Insulin-like Growth Factor II Gene,IGF2,in Sporadic Breast Carcinomas. Biochemical and Biophysical Research Communications, 1997, 235, 123-129.	2.1	52
152	Identification of a novel gene NCRMS on chromosome 12q21 with differential expression between Rhabdomyosarcoma subtypes. Oncogene, 2002, 21, 3029-3037.	5.9	52
153	Interactions and relationships of <i>PTEN</i> , <i>ERG</i> , <i>SPINK1</i> and <i>AR</i> in castrationâ€resistant prostate cancer. Histopathology, 2012, 60, 645-652.	2.9	52
154	Comparative Genomic Hybridization Analysis Detects Frequent Over-Representation of DNA Sequences at 3q, 7p, and 8q in Head and Neck Carcinomas. Cancer Genetics and Cytogenetics, 2000, 119, 48-55.	1.0	51
155	An integrated mBAND and submegabase resolution tiling set (SMRT) CCH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage–fusion–bridge cycle events in osteosarcoma. Genes Chromosomes and Cancer, 2005, 42, 392-403.	2.8	50
156	A phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. Investigational New Drugs, 2015, 33, 969-976.	2.6	50
157	Clonal heterogeneity of dendritic cells derived from patients with chronic myeloid leukemia and enhancement of their T-cells stimulatory activity by IFN-1±. Experimental Hematology, 1999, 27, 1176-1184.	0.4	49
158	Evidence of Chromosomal Instability in Prostate Cancer Determined by Spectral Karyotyping (SKY) and Interphase FISH Analysis. Neoplasia, 2001, 3, 62-69.	5.3	49
159	Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma. Journal of Molecular Diagnostics, 2011, 13, 289-296.	2.8	49
160	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genetics, 2011, 204, 525-535.	0.4	49
161	Digital Expression Profiling Identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as Potential Predictive Biomarkers for Neo-Adjuvant Chemotherapy Response in Paediatric Osteosarcoma. PLoS ONE, 2014, 9, e95843.	2.5	49
162	Structural Characterization and Mapping of the Normal Epithelial Cell-Specific 1 Gene. Biochemical and Biophysical Research Communications, 1998, 247, 580-586.	2.1	48

#	Article	IF	CITATIONS
163	Correlating breakage-fusion-bridge events with the overall chromosomal instability and in vitro karyotype evolution in prostate cancer. Cytogenetic and Genome Research, 2007, 116, 1-11.	1.1	48
164	Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma. Cancer Letters, 2007, 250, 284-291.	7.2	48
165	Modulation by decitabine of gene expression and growth of osteosarcoma U2OS cells in vitro and in xenografts: Identification of apoptotic genes as targets for demethylation. Cancer Cell International, 2007, 7, 14.	4.1	48
166	Molecular characterization of deletion breakpoints in adults with 22q11 deletion syndrome. Human Genetics, 2007, 120, 837-845.	3.8	48
167	The mammalian target of rapamycin pathway is widely activated without <i>PTEN</i> deletion in renal cell carcinoma metastases. Cancer, 2011, 117, 290-300.	4.1	48
168	Defining a 0.5-Mb Region of Genomic Gain on Chromosome 6p22 in Bladder Cancer by Quantitative-Multiplex Polymerase Chain Reaction. American Journal of Pathology, 2004, 164, 285-293.	3.8	47
169	Assignment of the Human Prostaglandin-Endoperoxide Synthase 2 (PTGS2) Gene to 1q25 by Fluorescence in Situ Hybridization. Genomics, 1994, 23, 718-719.	2.9	46
170	The breakage–fusion–bridge (BFB) cycle as a mechanism for generating genetic heterogeneity in osteosarcoma. Chromosoma, 2006, 115, 459-467.	2.2	46
171	Identification ofPFTAIREprotein kinase 1, a novel cell division cycle-2 related gene, in the motile phenotype of hepatocellular carcinoma cells. Hepatology, 2007, 46, 436-445.	7.3	46
172	Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2012, 7, 1513-1521.	1.1	46
173	Current state of biomarkers in ovarian cancer prognosis. Future Oncology, 2015, 11, 3187-3195.	2.4	45
174	Melanotic Neuroectodermal Tumor of Infancy: A Molecular Genetic Study. Pediatric and Developmental Pathology, 1998, 1, 295-299.	1.0	44
175	Quantitative real-time PCR identifies a critical region of deletion on 22q13 related to prognosis in oral cancer. Oncogene, 2002, 21, 6480-6487.	5.9	44
176	Telomere Attrition in Isolated High-Grade Prostatic Intraepithelial Neoplasia and Surrounding Stroma Is Predictive of Prostate Cancer. Neoplasia, 2007, 9, 81-89.	5.3	44
177	Cytogenetically balanced translocations are associated with focal copy number alterations. Human Genetics, 2007, 120, 795-805.	3.8	44
178	Characterization of abnormal one pronuclear human oocytes by morphology, cytogenetics and in-situ hybridization. Human Reproduction, 1993, 8, 402-408.	0.9	43
179	HER2 Amplification and Overexpression Is Not Present in Pediatric Osteosarcoma: A Tissue Microarray Study. Pediatric and Developmental Pathology, 2005, 8, 525-532.	1.0	43
180	<i>NKX3.1</i> Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy. Clinical Cancer Research, 2012, 18, 308-316.	7.0	43

#	Article	IF	CITATIONS
181	Localization of beckwith-wiedemann and rhabdoid tumor chromosome rearrangements to a defined interval in chromosome band 11p15.5. Genes Chromosomes and Cancer, 1994, 11, 97-105.	2.8	42
182	Selection for transgene homozygosity in embryonic stem cells results in extensive loss of heterozygosity. Nature Genetics, 2001, 27, 257-258.	21.4	42
183	Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma. Modern Pathology, 2006, 19, 1546-1554.	5.5	42
184	STAT1â€associated intratumoural T _H 1 immunity predicts chemotherapy resistance in highâ€grade serous ovarian cancer. Journal of Pathology: Clinical Research, 2016, 2, 259-270.	3.0	42
185	Astroblastoma: Report of a Case with Ultrastructural, Cell Kinetic, and Cytogenetic Analysis. Pediatric Pathology, 1993, 13, 323-332.	0.5	40
186	Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genetics and Cytogenetics, 2007, 179, 52-61.	1.0	40
187	Distinct Patterns of Structural and Numerical Chromosomal Instability Characterize Sporadic Ovarian Cancer. Neoplasia, 2008, 10, 1057-IN3.	5.3	40
188	Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Annals of Oncology, 2011, 22, 2403-2410.	1.2	40
189	The Orphan Nuclear Receptor RORα (RORA) Maps to a Conserved Region of Homology on Human Chromosome 15q21-q22 and Mouse Chromosome 9. Genomics, 1995, 28, 596-598.	2.9	39
190	High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenetic and Genome Research, 2004, 107, 77-82.	1.1	39
191	<i>TMPRSS2-ERG</i> Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209.	7.0	39
192	The Dual Role of Serotonin in Colorectal Cancer. Trends in Endocrinology and Metabolism, 2020, 31, 611-625.	7.1	39
193	Mapping of the Gene Encoding the Integrin-Linked Kinase, ILK, to Human Chromosome 11p15.5–p15.4. Genomics, 1997, 42, 177-179.	2.9	38
194	Complex rearrangement of chromosomes 19, 21, and 22 in Ewing sarcoma involving a novel reciprocal inversion–insertion mechanism of EWS–ERG fusion gene formation: a case analysis and literature review. Cancer Genetics and Cytogenetics, 2008, 181, 81-92.	1.0	38
195	Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics. Orphanet Journal of Rare Diseases, 2013, 8, 33.	2.7	38
196	Application of microarrays to the analysis of gene expression in cancer. Clinical Chemistry, 2002, 48, 1170-7.	3.2	38
197	Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Research, 2002, 62, 6194-204.	0.9	38
198	Transcriptional profiling of medulloblastoma in children. Journal of Neurosurgery, 2003, 99, 534-541.	1.6	36

#	Article	IF	CITATIONS
199	Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells. Laboratory Investigation, 2005, 85, 664-674.	3.7	36
200	Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia, 1999, 13, 105-109.	7.2	35
201	Combined spectral karyotyping, multicolor banding, and microarray comparative genomic hybridization analysis provides a detailed characterization of complex structural chromosomal rearrangements associated with gene amplification in the osteosarcoma cell line MG-63. Cancer Genetics and Cytogenetics. 2004. 153. 158-164.	1.0	35
202	Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biology and Therapy, 2011, 11, 562-566.	3.4	35
203	Contributions of HOX genes to cancer hallmarks: Enrichment pathway analysis and review. Tumor Biology, 2020, 42, 101042832091805.	1.8	35
204	Oncogene amplification in medulloblastoma: analysis of a case by comparative genomic hybridization and fluorescence in situ hybridization. Pathology, 1999, 31, 337-344.	0.6	34
205	Chromosomal Mapping of the Human and Murine Orphan Receptors ERRα (ESRRA) and ERRβ (ESRRB) and Identification of a Novel Human ERRα-Related Pseudogene. Genomics, 1997, 45, 320-326.	2.9	33
206	Spontaneous blastomere fusion after freezing and thawing of early human embryos leads to polyploidy and chromosomal mosaicism. Human Reproduction, 2000, 15, 2404-2410.	0.9	33
207	Quantitative PCR identifies a minimal deleted region of 120 kb extending from the Philadelphia chromosome ABL translocation breakpoint in chronic myeloid leukemia with poor outcome. Leukemia, 2003, 17, 1313-1323.	7.2	33
208	The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression. Translational Oncology, 2012, 5, 453-460.	3.7	33
209	Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 16930-16935.	7.1	32
210	In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 607-617.	2.8	32
211	Molecular Cytogenetic Analysis of Glial Tumors Using Spectral Karyotyping and Comparative Genomic Hybridization. Molecular Diagnosis and Therapy, 2001, 6, 93-108.	1.1	32
212	Promoter-Dependent Tissue-Specific Expressive Nature of Imprinting Gene, Insulin-like Growth Factor II, in Human Tissues. Biochemical and Biophysical Research Communications, 1997, 233, 221-226.	2.1	31
213	Variant EWS-WT1 Chimeric Product in the Desmoplastic Small Round Cell Tumor. Pediatric and Developmental Pathology, 1999, 2, 188-192.	1.0	31
214	Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. Journal of Clinical Pathology, 2006, 60, 426-428.	2.0	31
215	Development of metastatic and nonâ€metastatic tumor lines from a patient's prostate cancer specimen—identification of a small subpopulation with metastatic potential in the primary tumor. Prostate, 2010, 70, 1636-1644.	2.3	31
216	Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems. Neoplasia, 2013, 15, 939-IN27.	5.3	31

#	Article	IF	CITATIONS
217	Genomic amplification in retinoblastoma narrowed to 0.6 megabase on chromosome 6p containing a kinesin-like gene, RBKIN. Cancer Research, 2002, 62, 967-71.	0.9	30
218	Variant translocations of chromosome 22 in Ewing's sarcoma. Genes Chromosomes and Cancer, 1993, 8, 190-194.	2.8	29
219	De novo 1q32q44 duplication and distal 1q trisomy syndrome. American Journal of Medical Genetics Part A, 2003, 120A, 229-233.	2.4	29
220	Distinct subtypes of genomic PTEN deletion size influence the landscape of aneuploidy and outcome in prostate cancer. Molecular Cytogenetics, 2018, 11, 1.	0.9	29
221	Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. International Journal of Oncology, 2005, 27, 1029-37.	3.3	29
222	Genomic Alterations in Sporadic Synchronous Primary Breast Cancer Using Array and Metaphase Comparative Genomic Hybridization. Neoplasia, 2007, 9, 511-520.	5.3	28
223	Prostate Cancer as a Model System for Genetic Diversity in Tumors. Advances in Cancer Research, 2011, 112, 183-216.	5.0	28
224	Intracranial and spinal metastases from a ganglioglioma with unusual cytogenetic abnormalities in a patient with complex partial seizures. Child's Nervous System, 1997, 13, 550-555.	1.1	27
225	The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics, 2006, 7, 65.	2.8	27
226	Application and interpretation of FISH in biomarker studies. Cancer Letters, 2007, 249, 97-109.	7.2	27
227	Genetic Characterization of Immortalized Human Prostate Epithelial Cell Cultures. Cancer Genetics and Cytogenetics, 2000, 120, 50-57.	1.0	26
228	Comparative genomic hybridization detects novel amplifications in fibroadenomas of the breast. Genes Chromosomes and Cancer, 2001, 30, 25-31.	2.8	26
229	Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. International Journal of Oncology, 2005, 27, 1029.	3.3	26
230	Serotonin synthesis protects the mouse colonic crypt from DNA damage and colorectal tumorigenesis. Journal of Pathology, 2019, 249, 102-113.	4.5	26
231	Re-evaluation of the sublocalization of esterase D and its relation to the retinoblastoma locus by in situ hybridization. Cytogenetic and Genome Research, 1987, 44, 153-157.	1.1	25
232	Assessment of <i>Mycn</i> Amplification in Neuroblastoma Biopsies by Differential Polymerase Chain Reaction. Pediatric Pathology, 1994, 14, 823-832.	0.5	25
233	Localization of the Interferon-Induced, 2-5A-Dependent RNase Gene (RNS4) to Human Chromosome 1q25. Genomics, 1994, 19, 174-175.	2.9	25
234	Molecular cytogenetic analysis in the study of brain tumors: findings and applications. Neurosurgical Focus, 2005, 19, 1-36.	2.3	25

#	Article	IF	CITATIONS
235	Multiple CDK/CYCLIND genes are amplified in medulloblastoma and supratentorial primitive neuroectodermal brain tumor. Cancer Genetics, 2012, 205, 220-231.	0.4	25
236	Increased STAT1 Expression in High Grade Serous Ovarian Cancer Is Associated With a Better Outcome. International Journal of Gynecological Cancer, 2018, 28, 459-465.	2.5	25
237	Prenatal diagnosis and outcome of pregnancy in 2036 women investigated by amniocentesis. Human Genetics, 1982, 61, 215-222.	3.8	24
238	Localization of the Human Interferon-Induced, ds-RNA Activated p68 Kinase Gene (PRKR) to Chromosome 2p21-p22. Genomics, 1993, 16, 768-770.	2.9	24
239	Lack of BCR/ABL reciprocal fusion in variant Philadelphia chromosome translocations: a use of double fusion signal FISH and spectral karyotyping. Leukemia, 2000, 14, 1157-1160.	7.2	24
240	Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci. Cancer Genetics and Cytogenetics, 2002, 137, 15-22.	1.0	24
241	DNA methylation in the CTCF-binding site I and the expression pattern of theH19 gene: Does positive expression predict poor prognosis in early stage head and neck carcinomas?. Molecular Carcinogenesis, 2005, 44, 102-110.	2.7	24
242	Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia. BMC Genomics, 2006, 7, 138.	2.8	24
243	Molecular Genetics in the Diagnosis and Prognosis of Solid Pediatric Tumors. Pediatric and Developmental Pathology, 1998, 1, 337-365.	1.0	23
244	Cloning and Characterization of the Human Retina-Specific Gene MPP4, a Novel Member of the p55 Subfamily of MAGUK Proteins. Genomics, 2001, 74, 377-384.	2.9	23
245	Use of whole genome amplification and comparative genomic hybridisation to detect chromosomal copy number alterations in cell line material and tumour tissue. Cytogenetic and Genome Research, 2004, 105, 18-24.	1.1	23
246	Prostatic preneoplasia and beyond. Biochimica Et Biophysica Acta: Reviews on Cancer, 2008, 1785, 156-181.	7.4	23
247	Relational mapping ofMYCN andDDX1 in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH. Genes Chromosomes and Cancer, 1997, 20, 243-252.	2.8	22
248	Comparative genomic hybridization analysis of clear cell sarcoma of the kidney. , 2000, 34, 113-116.		22
249	Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics. Genes, 2021, 12, 1900.	2.4	22
250	Transcriptional profiling identifies gene expression changes associated with IFN-alpha tolerance in hepatitis C-related hepatocellular carcinoma cells. Clinical Cancer Research, 2005, 11, 1319-26.	7.0	22
251	Genomic instability and copyâ€number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas. Molecular Oncology, 2011, 5, 48-60.	4.6	21
252	Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies. Prostate, 2011, 71, 778-790.	2.3	21

#	Article	IF	CITATIONS
253	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). Journal of the National Cancer Institute, 2020, 112, 1098-1104.	6.3	21
254	Identification of Numerical Chromosomal Changes Detected by Interphase Fluorescence In Situ Hybridization in High-Grade Prostate Intraepithelial Neoplasia as a Predictor of Carcinoma. Archives of Pathology and Laboratory Medicine, 2002, 126, 165-169.	2.5	21
255	Global analysis of chromosome X gene expression in primary cultures of normal ovarian surface epithelial cells and epithelial ovarian cancer cell lines. International Journal of Oncology, 2007, , .	3.3	20
256	Characterization of trisomy 8 in pediatric undifferentiated sarcomas using advanced molecular cytogenetic techniques. Cancer Genetics and Cytogenetics, 2007, 174, 35-41.	1.0	20
257	Novel 6p rearrangements and recurrent translocation breakpoints in retinoblastoma cell lines identified by spectral karyotyping and mBAND analyses. Cancer Genetics and Cytogenetics, 2007, 179, 102-111.	1.0	20
258	Stem cell enrichment approaches. Seminars in Cancer Biology, 2007, 17, 257-264.	9.6	20
259	A heat shock gene at 14q22: mapping and expression. Human Molecular Genetics, 1994, 3, 1819-1822.	2.9	19
260	Use of Multicolor Spectral Karyotyping in Genetic Analysis of Pleuropulmonary Blastoma. Pediatric and Developmental Pathology, 2000, 3, 479-486.	1.0	19
261	Analysis of Chromosome 22q as an Aid to the Diagnosis of Rhabdoid Tumor. American Journal of Surgical Pathology, 1999, 23, 982.	3.7	19
262	Application of a Simplified Comparative Genomic Hybridization Technique to Screen for Gene Amplification in Pediatric Solid Tumors. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1995, 15, 831-844.	0.3	18
263	Molecular genetics of pineal region neoplasms. Journal of Neuro-Oncology, 2001, 54, 219-238.	2.9	18
264	Multi-Color FISH Techniques. , 2004, Chapter 22, Unit 22.5.		18
265	Genomic alterations detected by comparative genomic hybridization in ovarian endometriomas. Brazilian Journal of Medical and Biological Research, 2010, 43, 799-805.	1.5	18
266	Maternal gametic transmission of translocations or inversions of human chromosome 11p15.5 results in regional DNA hypermethylation and downregulation of CDKN1C expression. Genomics, 2012, 99, 25-35.	2.9	18
267	Evolution of 8p loss in transformed human prostate epithelial cells. Cancer Genetics and Cytogenetics, 2004, 154, 36-43.	1.0	17
268	Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology: Erratum. Journal of Thoracic Oncology, 2013, 8, 1343.	1.1	17
269	Smoking-induced chromosomal segregation anomalies identified by FISH analysis of sperm. Molecular Cytogenetics, 2014, 7, 58.	0.9	17
270	Molecular and Cytogenetic Analysis of a Cerebellar Primitive Neuroectodermal Tumor with Prominent Neuronal Differentiation: Detection of MYCN Amplification by Differential Polymerase Chain Reaction and Southern Blot Analysis. Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1995, 15, 733-744.	0.3	16

#	Article	IF	CITATIONS
271	Expression of WT1 in Pediatric Small Cell Tumors: Report of Two Cases with a Possible Mesothelial Origin. Pediatric and Developmental Pathology, 1999, 2, 33-41.	1.0	16
272	Hemangioendothelioma of Bone in a Patient with a Constitutional Supernumerary Marker. Cancer Genetics and Cytogenetics, 1999, 110, 23-27.	1.0	16
273	p53 Alteration and Chromosomal Instability in Prostatic High-Grade Intraepithelial Neoplasia and Concurrent Carcinoma: Analysis by Immunohistochemistry, Interphase In Situ Hybridization, and Sequencing of Laser-Captured Microdissected Specimens. Modern Pathology, 2001, 14, 1252-1262.	5.5	16
274	Microarray CGH. , 2002, 204, 191-208.		16
275	Traditional Banding of Chromosomes for Cytogenetic Analysis. Current Protocols in Cell Biology, 2004, 23, Unit 22.3.	2.3	16
276	The use of cytogenetics in understanding ovarian cancer. Biomedicine and Pharmacotherapy, 2004, 58, 17-23.	5.6	16
277	Transcriptional profiling on chromosome 19p indicated frequent downregulation of <i>ACP5</i> expression in hepatocellular carcinoma. International Journal of Cancer, 2005, 114, 902-908.	5.1	16
278	Impact of cytogenetic and genomic aberrations of the kallikrein locus in ovarian cancer. Molecular Oncology, 2008, 2, 250-260.	4.6	16
279	Analysis of Segmental Duplications, Mouse Genome Synteny and Recurrent Cancer-Associated Amplicons in Human Chromosome 6p21–p12. Cytogenetic and Genome Research, 2010, 128, 199-213.	1.1	16
280	Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics. Cancers, 2012, 4, 725-742.	3.7	16
281	Molecular cytogenetic analysis of glial tumors using spectral karyotyping and comparative genomic hybridization. Molecular Diagnosis and Therapy, 2001, 6, 93-108.	1.1	16
282	Preparation of Cytogenetic Specimens from Tissue Samples. Current Protocols in Cell Biology, 2004, 23, Unit 22.2.	2.3	15
283	Sister Chromatid Exchange. Current Protocols in Cell Biology, 2004, 25, Unit 22.7.	2.3	15
284	Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes and Cancer, 2006, 45, 136-146.	2.8	15
285	High definition cytogenetics and oligonucleotide aCGH analyses of cisplatinâ€resistant ovarian cancer cells. Genes Chromosomes and Cancer, 2008, 47, 427-436.	2.8	15
286	Caspase-8 is essential for maintaining chromosomal stability and suppressing B-cell lymphomagenesis. Blood, 2012, 119, 3495-3502.	1.4	15
287	Copy Number and Expression Alterations of miRNAs in the Ovarian Cancer Cell Line OVCAR-3: Impact on Kallikrein 6 Protein Expression. Clinical Chemistry, 2013, 59, 296-305.	3.2	15
288	The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 9550.	4.1	15

#	Article	IF	CITATIONS
289	Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clinical Cancer Research, 2005, 11, 621-31.	7.0	15
290	Identification of MYCN Copy Number Heterogeneity by Direct FISH Analysis of Neuroblastoma Preparations. Molecular Diagnosis and Therapy, 1996, 1, 281-289.	1.1	15
291	Genomic imprinting in tumours. Seminars in Cancer Biology, 1996, 7, 41-47.	9.6	14
292	Familial Evans Syndrome. Journal of Pediatric Hematology/Oncology, 1999, 21, 244-247.	0.6	14
293	Chromosome 22q a frequent site of allele loss in head and neck carcinoma. Head and Neck, 2000, 22, 585-590.	2.0	14
294	Microdeletion and concurrent translocation associated with a complexTMPRSS2:ERG prostate cancer gene fusion. Genes Chromosomes and Cancer, 2007, 46, 861-863.	2.8	14
295	Epigenetic and Phenotypic Consequences of a Truncation Disrupting the Imprinted Domain on Distal Mouse Chromosome 7. Molecular and Cellular Biology, 2008, 28, 1092-1103.	2.3	14
296	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	1.4	14
297	Juvenile Chronic Myelogenous Leukemia Multilineage CD34+Cells: Aberrant Growth and Differentiation Properties. Stem Cells, 1996, 14, 690-701.	3.2	13
298	Heterogeneity of <i>MYCN </i> Amplification in a Child with Stroma-Rich Neuroblastoma (Ganglioneuroblastoma). Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 875-883.	0.3	13
299	Alterations of H19 Imprinting and IGF2 Replication Timing Are Infrequent in Beckwith–Wiedemann Syndrome. Genomics, 2000, 65, 234-242.	2.9	13
300	High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts. Modern Pathology, 2021, 34, 478-489.	5.5	13
301	Expression of major vault protein gene in osteosarcoma patients. Journal of Orthopaedic Research, 2007, 25, 958-963.	2.3	12
302	The interval between Ins2 and Ascl2 is dispensable for imprinting centre function in the murine Beckwith–Wiedemann region. Human Molecular Genetics, 2009, 18, 4255-4267.	2.9	12
303	Karyotype/phenotype correlation in partial trisomies of the long arm of chromosome 16: Case report and review of literature. American Journal of Medical Genetics, Part A, 2012, 158A, 821-827.	1.2	12
304	Clinical applications of genetic rearrangements in cancer. Seminars in Cancer Biology, 1996, 7, 25-32.	9.6	11
305	Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America. Cancer Genetics and Cytogenetics, 2006, 170, 40-47.	1.0	11
306	A newly characterized human well-differentiated liposarcoma cell line contains amplifications of the 12q12-21 and 10p11-14 regions. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 67-78.	2.8	11

#	Article	IF	CITATIONS
307	Mapping of the gonadotropin-releasing hormone (GnRH) receptor gene to human Chromosome 4q21.2 by fluorescence in situ hybridization. Mammalian Genome, 1995, 6, 309-310.	2.2	10
308	Reduced tumorigenesis in p53 knockout mice exposed in utero to lowâ€dose vitamin E. Cancer, 2009, 115, 1563-1575.	4.1	10
309	Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. Laboratory Investigation, 2018, 98, 403-413.	3.7	10
310	Identification of a high frequency of chromosomal rearrangements in the centromeric regions of prostate cancer cell lines by sequential Giemsa banding and spectral karyotyping. Molecular Diagnosis and Therapy, 2000, 5, 23-32.	1.1	9
311	Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literature. Journal of Neurosurgery: Pediatrics, 2004, 101, 85-90.	1.3	9
312	Analysis of genomic abnormalities in tumors: a review of available methods for Illumina two-color SNP genotyping and evaluation of performance. Cancer Genetics, 2013, 206, 103-115.	0.4	9
313	Composite Mantle Cell and Primary Cutaneous Anaplastic Large Cell Lymphoma. American Journal of Dermatopathology, 2015, 37, 232-236.	0.6	9
314	HETEROGENEITY OF MYCN AMPLIFICATION IN A CHILD WITH STROMA-RICH NEUROBLASTOMA (GANGLIONEUROBLASTOMA). Pediatric Pathology & Laboratory Medicine: Journal of the Society for Pediatric Pathology, Affiliated With the International Paediatric Pathology Association, 1997, 17, 875-884.	0.3	9
315	Identification of a novel zinc finger gene,zf5-3, as a potential mediator of neuroblastoma differentiation. , 1999, 81, 970-978.		8
316	Comparative genomic hybridization analysis of benign and invasive male breast neoplasms. Cancer Genetics and Cytogenetics, 2002, 134, 123-126.	1.0	8
317	Hydrocephaly, penoscrotal transposition, and digital anomalies associated with de novo pseudodicentric rearranged chromosome 13 characterized by classical cytogenetic methods and mBAND analysis. American Journal of Medical Genetics, Part A, 2006, 140A, 1321-1325.	1.2	8
318	The human UDPâ€ <i>N</i> â€Acetylglucosamine:αâ€6â€ <scp>d</scp> â€Mannosideâ€Î²â€1,2â€ <i>N</i> â€Acetylglucosa Gene (<i>MGAT2</i>). FEBS Journal, 1995, 231, 317-328.	nin øtz ansf	erase II
319	Integrated Cytogenetic and High-Resolution Array CGH Analysis of Genomic Alterations Associated with <i>MYCN</i> Amplification. Cytogenetic and Genome Research, 2011, 134, 27-39.	1.1	8
320	Pediatric malignant glioma with tubuloreticular inclusions and MYCN amplification. Report of a case with immunohistochemical, ultrastructural, flow cytometric, karyotypic, and southern blot analysis. Cancer, 1994, 73, 1987-1993.	4.1	7
321	Spectral Karyotyping. , 2002, 204, 85-104.		7
322	Comparative Genomic Hybridization. Current Protocols in Cell Biology, 2004, 25, Unit 22.6.	2.3	7
323	A rare case of trisomy 15pterâ€q21.2 due to a de novo marker chromosome. American Journal of Medical Genetics, Part A, 2010, 152A, 753-758.	1.2	7
324	Prognostic impact of adenomatous polyposis coli gene expression in osteosarcoma of the extremities. European Journal of Cancer, 2010, 46, 3307-3315.	2.8	7

#	Article	IF	CITATIONS
325	Molecular characterization of short-term primary cultures and comparison with corresponding tumor tissue of Brazilian glioblastoma patients. Translational Cancer Research, 2017, 6, 332-345.	1.0	7
326	Mitochondrial ATP synthase α-subunit gene amplified in a retinoblastoma cell line maps to chromosome 18. Genes Chromosomes and Cancer, 1995, 14, 63-67.	2.8	6
327	Cytogenetic molecular delineation of a terminal 18q deletion suggesting neo-telomere formation. European Journal of Medical Genetics, 2010, 53, 404-407.	1.3	5
328	Selection of probes for fluorescence in situ hybridization analysis by differential display polymerase chain reaction of mRNA from rhabdomyosarcoma. Cancer Genetics and Cytogenetics, 1996, 92, 58-65.	1.0	4
329	Offâ€gas treatment carbon footprint calculator: Form and function. Remediation, 2008, 19, 39-51.	2.4	4
330	Sequential G-banding, SKY and FISH provide a refined identification of translocation breakpoints and complex chromosomal rearrangements. Technical Tips Online, 1999, 4, 66-69.	0.2	3
331	Acute monocytic leukemia and multiple abnormalities in a child with duplication of 1q detected by GTG-banding and SKY. Leukemia Research, 2005, 29, 1465-1467.	0.8	3
332	Sustainable soil remediation by refrigerated condensation at sites with "high-concentration― recalcitrant compounds and NAPL: Two case studies. , 2008, 19, 53-72.		3
333	First application of the Automated QUantitative Analysis (AQUA) technique to quantify PTEN protein expression in ovarian cancer: A correlative study of NCIC CTG OV.16. Gynecologic Oncology, 2016, 140, 486-493.	1.4	3
334	Complex Mosaic Ring Chromosome 11 Associated with Hemizygous Loss of 8.6 Mb of 11q24.2qter in Atypical Jacobsen Syndrome. Molecular Syndromology, 2017, 8, 45-49.	0.8	3
335	Phase II study of PX-866 in recurrent glioblastoma Journal of Clinical Oncology, 2013, 31, 2053-2053.	1.6	3
336	Advanced Cancer Genetics in Neurosurgical Research. Neurosurgery, 2003, 53, 1168-1178.	1.1	2
337	Lacrimal gland anaplastic kinase–positive large Bâ€cell lymphoma (LBCLâ€ALK+) with an atypical clinical presentation. Clinical and Experimental Ophthalmology, 2016, 44, 520-522.	2.6	2
338	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. Expert Review of Molecular Diagnostics, 2021, 21, 161-173.	3.1	2
339	Fluorescence In Situ Hybridization. Springer Protocols, 2008, , 239-255.	0.3	2
340	Association of PTEN protein loss with upgrading of prostate cancer from biopsy to radical prostatectomy Journal of Clinical Oncology, 2014, 32, 127-127.	1.6	2
341	Genetic alterations in doxorubicin-resistant hepatocellular carcinoma cells: a combined study of spectral karyotyping, positional expression profiling and candidate genes. International Journal of Oncology, 2004, 25, 1357-64.	3.3	2
342	Allelic fusion of DNA topoisomerase IIα and retinoic acid receptor α genes in Adriamycin-resistant p388 murine leukemia revealed by fluorescence in situ hybridization. Cytogenetic and Genome Research, 1996, 75, 164-166.	1.1	1

#	Article	IF	CITATIONS
343	Overview of Cytogenetic Chromosome Analysis. Current Protocols in Cell Biology, 2004, 23, Unit 22.1.	2.3	1
344	Genetic Aspects of Bone Tumors. , 2010, , 161-170.		1
345	SINGLE CELL DERIVED CLONAL ANALYSIS OF HUMAN GLIOBLASTOMA LINKS FUNCTIONAL AND GENOMIC HETEROGENEITY. Neuro-Oncology, 2014, 16, iii14-iii14.	1.2	1
346	Centrosome amplification in chondrosarcomas: A primary cell culture and cryopreserved tumor sample study. Oncology Letters, 2017, 13, 1835-1835.	1.8	1
347	Mining Extracellular Vesicles for Clinically Relevant Noninvasive Diagnostic Biomarkers in Cancer. , 0, , .		1
348	The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors Journal of Clinical Oncology, 2013, 31, 11085-11085.	1.6	1
349	Molecular Genetic Changes in Alveolar Soft Part Sarcoma. Fetal and Pediatric Pathology, 1998, 18, 529-543.	0.7	1
350	Chromosomal imbalances detected in primary bone tumors by comparative genomic hybridization and interphase fluorescence in situ hybridization. Genetics and Molecular Biology, 2003, 26, 107-113.	1.3	1
351	Heterogeneity of MYCN Amplification in a Child with Stroma-Rich Neuroblastoma (Ganglioneuroblastoma). Fetal and Pediatric Pathology, 1997, 17, 875-883.	0.7	1
352	Characterization of human hepatocyte lines derived from normal liver tissue. Hepatology, 1994, 19, 1390-1399.	7.3	1
353	Genetic origin of mutations predisposing to retinoblastoma. Survey of Ophthalmology, 1986, 31, 141-142.	4.0	0
354	Introduction: Genetic rearrangements in cancer. Seminars in Cancer Biology, 1996, 7, 1.	9.6	0
355	Molecular Genetic Changes in Alveolar Soft Part Sarcoma. Fetal and Pediatric Pathology, 1998, 18, 529-543.	0.3	0
356	Role of New Cytogenetic Methodologies in the Management of Acute Myeloid Leukemia. Leukemia and Lymphoma, 1998, 30, 37-37.	1.3	0
357	2 Comparative genomic hybridization analysis using metaphase or microarray slides. Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas, 2002, 2, 11-21.	0.0	0
358	Detection of Mitotic Figures and Components of the Mitotic Machinery. Current Protocols in Cell Biology, 2004, 25, Unit 22.8.	2.3	0
359	133 EVALUATION OF PTEN AND TMPRSS2-ERG ABNORMALITIES IN PROSTATE CANCER BY FISH AND IMMUNOHISTOCHEMISTRY TO ADDRESS INTRA- AND INTER- TISSUE HETEROGENEITY AND DISEASE PROGRESSION. Journal of Urology, 2011, 185, .	0.4	0
360	1607 HIGH-RESOLUTION DETECTION OF PTEN GENOMIC DELETION BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH) USING 330 FIXED PARAFFIN-EMBEDDED TISSUE SAMPLES. Journal of Urology, 2011, 185, .	0.4	0

#	Article	IF	CITATIONS
361	2136 APPLICATION OF FOUR COLOR FLUORESCENCE IN SITU HYBRIDIZATION IDENTIFIES GENOMIC DELETIONS OF THE PTEN GENE IN 384 OF 2115 (18.2%) DIAGNOSTIC PROSTATE CANCER-POSITIVE NEEDLE CORES. Journal of Urology, 2013, 189, .	0.4	0
362	MP79-14 FISH ANALYSIS OF 637 PROSTATE CANCERS: ASSOCIATION OF PTEN GENOMIC DELETION WITH EARLIER ONSET OF DISEASE PROGRESSION AND WORSE PROGNOSIS. Journal of Urology, 2014, 191, .	0.4	0
363	MP1-17 PTEN STATUS DETERMINATION IN PROSTATE CANCER: COMPARISON OF IHC AND FISH IN A LARGE MULTI-CENTER COHORT. Journal of Urology, 2015, 193, .	0.4	0
364	Genetic aspects of bone tumors. , 2015, , 305-318.		0
365	Partial Monosomy 4p and Trisomy 12q due to a t(4;12)(p16.3;q24.31) Familial Translocation in Two Cousins. Molecular Syndromology, 2019, 10, 264-271.	0.8	0
366	Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. , 2019, , 149-162.		0
367	Genetic aspects of primary bone tumors. , 2022, , 531-542.		0
368	Abstract 3037: Integrated Genomic, MicroRNA (miRNA) and Proteomic Profiling of Ovarian Carcinoma for Biomarker Discovery. , 2010, , .		0
369	Abstract 2136: Combined 8q gain and 10q loss predicts for relapse following radical radiotherapy in intermediate risk prostate cancer. , 2010, , .		0
370	Abstract 326: Prognostic value of KIF14 and MDM4 in Ewing's sarcoma. , 2010, , .		0
371	Abstract 3404: Identification of potential oncogenes in osteosarcoma pathogenesis by high-resolution array comparative genomic hybridization. , 2010, , .		0
372	Abstract 320: Fine structure genomic mapping of chromosome 10q23 interstitial deletions in prostate cancer reveals thePTENgene locus as the minimum region deleted. , 2010, , .		0
373	Abstract 320: Association of higher Gleason grade with presence of PTEN deletion in prostatic adenocarcinoma. , 2011, , .		0
374	Abstract 3207: Automated quantitative analysis of p53, cyclin D1 and pErk expression in breast carcinoma does not differ from expert pathologist scoring and correlates well with clinico-pathological characteristics. , 2011, , .		0
375	Abstract 317: 1q32.1 and 16q21 genomic alterations implicate KIF14/MDM4/PIK3C2ß and CDH11 as independent prognostic markers of relapse in localized Ewing Family of Tumors. , 2011, , .		0
376	Abstract 1168: Integrated genomic, microRNA (miRNA) and proteomic profiling by stable isotope labeling with amino acids in cell culture (SILAC) of ovarian carcinoma for biomarker discovery. , 2011, , .		0
377	Abstract 1719: Integrative genomic analysis of ovarian cancer cell lines points to EMT involvement in the development of cisplatin resistance. , 2011, , .		0
378	TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer Journal of Clinical Oncology, 2012, 30, 11-11.	1.6	0

#	Article	IF	CITATIONS
379	Abstract 3004: Biomarker identification through integrative bioinformatics analysis of serous epithelial ovarian cancer tumor samples. , 2012, , .		Ο
380	Abstract 2999: Gene expression signature of differential response to chemotherapy in sporadic pediatric osteosarcoma. , 2012, , .		0
381	Phase II study of PX-866 in recurrent glioblastoma Journal of Clinical Oncology, 2012, 30, 2051-2051.	1.6	0
382	Abstract A53: Biomarkers of chemotherapy resistance in serous epithelial ovarian cancer identified by integrative genomic and transcriptomic analysis. , 2013, , .		0
383	Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. , 2015, , 159-175.		0
384	Abstract 1106: The tumor immune microenvironment modulates response to chemotherapy in high-grade serous epithelial ovarian cancer. , 2014, , .		0
385	Abstract 716: STAT1 expression in the tumor-stroma microenvironment is influenced by loss of PTEN in prostate cancer. , 2016, , .		0
386	Abstract 441: Association of interferon inducible genes with tumor immune microenvironment and chemotherapy resistance in high-grade serous epithelial ovarian cancer. , 2016, , .		0
387	MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER Journal of Urology, 2019, 201, .	0.4	0